Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong maintains an Equal-Weight rating on Nevro (NYSE:NVRO) and lowers the price target from $40 to $29.
May 31, 2023 | 11:38 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Nevro and lowers the price target from $40 to $29.
The lowered price target from $40 to $29 by Morgan Stanley analyst Cecilia Furlong indicates a bearish outlook on Nevro's stock. This could lead to a short-term negative impact on the stock price as investors may adjust their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100